Korea FDA Begins Consultation Services Akin To U.S. FDA's Special Protocol Assessment
This article was originally published in PharmAsia News
Consultations with KFDA’s National Institute of Food and Drug Safety Evaluation aim to benefit new innovative players, but drug approval process remains independent.
You may also be interested in...
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.